News Novo builds pipeline again with $2.1bn Omeros deal Novo Nordisk has boosted its pipeline by paying $340m upfront for rights to an Omeros drug for PNH and other rare blood and kidney disorders.
News Omeros seeks urgent FDA meeting after it rejects key drug Shares in Omeros plummeted yesterday after the FDA rejected approval of its narsoplimab drug for a rare and life-threatening complication of haematopoietic stem cell transplants (HSCT), say
News Breakthrough status for nephropathy drug lifts Omeros The FDA has given breakthrough therapy designation to OMS721, a new treatment for the
News Rival to rare disease blockbuster Soliris moves ahead Seattle-based biotech firm Omeros says its pipeline treatment to rival Alexion's Soliris is set to enter phase 3 later this year.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.